Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 5/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738169 | 1.00 | HPGD (0.49) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL16172595 | 0.91 | HPGD (0.49) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL24359101 | 0.86 | HPGD (0.54) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL26197 | 0.86 | ADORA2A (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL26198 | 0.86 | ADORA2A (0.58) | HPGDHINT1NT5ETAS1R3TAS1R1 | |
| SCHEMBL7614834 | 0.85 | HPGD (0.59) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL7614827 | 0.85 | HPGD (0.59) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL5982371 | 0.85 | ADORA2A (0.51) | NT5EADORA2AADORA2B | |
| SCHEMBL1737176 | 0.85 | ADORA2A (0.51) | NT5EADORA2AADORA2B | |
| SCHEMBL5963095 | 0.85 | ADORA2A (0.59) | HPGDHINT1NT5EADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | claimed |
| US-7101993-B1 | Oligonucleotides containing 2′-O-modified purines | ISIS PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7037646-B1 | Amine-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1223173-B1 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS INC (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| EP-0651759-B1 | NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF | ISIS PHARMACEUTICALS INC (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-0728139-B1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6242592-B1 | Process for the preparation of 2′-O-alkyl-guanosine, cytidine, and uridine phosphoramidites | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| US-6133438-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5856466-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5646265-A | Process for the preparation of 2'-O-alkyl purine phosphoramidites | ISIS PHARMCEUTICALS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | HPGD 3054/4885HINT1 895/4885NT5E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.